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ABSTRACT
Before the Controlled Substance Act of 1985 categorized psychedelic substances
as criminalized schedule I drugs, psychiatrists used ±3,4methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy. Over two
decades later, this project seeks to contribute to the renaissance of psychedelic research.
Specifically, this study focuses on participants’ experience of treatment in the recent
FDA approved Phase 2 clinical study, “A Randomized, Triple-Blind Phase 2 Pilot Study
Comparing 3 Different Doses of MDMA in conjunction with manualized psychotherapy
in 24 Veterans, Firefighters, and Police Officers with Chronic, Treatment-resistant
PTSD.” The current study presents results from correlation analyses of the Mystical
Experience Questionnaire (MEQ30) with PTSD symptom improvement to determine
whether outcomes are related to mystical experiences.
Mystical experiences are often described by people under the influence of
psychedelics; however, that experience with MDMA is not correlated with long-term
positive symptom change as reported by participants during long-term follow-up (LTFU)
interviews and Clinician-Administered PTSD Scale (CAPS) scores.
Keywords
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CHAPTER I
Introduction
Traumatic events such as war, natural disaster, sexual abuse, oppression, childhood
neglect, violence, and accidents, can cause a psychiatric condition called posttraumatic stress
disorder (PTSD). According to the fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM V-TR), the four primary symptom categories for PTSD include arousal
and reactivity, avoidance of triggers, negative thoughts and feelings, and intrusive thoughts and
nightmares (APA, 2013). Currently, the mental health field is facing a staggering suicide
increase, an overdose epidemic, and has largely failed the majority of people who need mental
health services the most, those experiencing PTSD. However, as some stigma against the use of
psychoactive drugs in the United States changes, a new era of research is emerging that utilizes
hallucinogenic or psychedelic drugs such as lysergic acid diethylamide (LSD), psilocybin,
ayahuasca, and ±3,4-methylenedioxymethamphetamine (MDMA) to treat pervasive mental
health disorders like PTSD. Conversely, interrupted by the Nixon Administration’s Controlled
Substance Act of 1970 (CSA), researchers in this important field have faced substantial obstacles
in learning more about psychedelic-assisted psychotherapy and its potential to reduce human
suffering.
The Controlled Substance Act attempted to regulate drug importation, use, possession,
and distribution in America by sorting substances into “schedules” and by implementing the
Drug Enforcement Agency (DEA). The law established what President Nixon called, “the War
on Drugs,” in an attempt to make America completely drug-free. However, despite the billions of
dollars that went into fighting what Reagan later deemed, “public enemy number one,” and
incarcerating unprecedented numbers of people of color for minor drug offenses, and filling

7

prisons with twice as many people than capacity, drug use and drug-related crime have not
decreased at all. Not only did the law fail to achieve what it set out to do, but it also put the
United States deeply in debt and substantially contributed to systemic racism. Recent news has
emerged showing that Nixon’s endorsement of anti-drug sentiment was entirely political and
racially motivated. Nixon’s domestic political chief John Ehrlichman said, “We knew we
couldn't make it illegal to be either against the war or blacks, but by getting the public to
associate the hippies with marijuana and blacks with heroin and then criminalizing both heavily,
we could disrupt those communities. We could arrest their leaders, raid their homes, break up
their meetings, and vilify them night after night on the evening news. Did we know we were
lying about the drugs? Of course we did (LoBianco, 2016, p. 1).”
Researcher, William Richards (2015) explains that the CSA included psychedelic
substances in “the highly restricted Category I.” This category includes drugs with absolutely no
accepted use, including medical, in the U.S and are also considered to have high abuse potential
(2015). This inclusion of psychedelic drugs such as LSD, psilocybin, and MDMA into this
category was unjustified when we knew then, thanks to research in the 1960s (Leary, 1964), and
know even more now, that evidence strongly indicates that these drugs can be safely
administered for substantial medically positive results, are nontoxic, and are nonaddictive.
Nixon’s policy alone completely shut down psychedelic research for twenty-two years (2015).
It is also worth noting that one of the most dangerous and readily available drugs,
alcohol, is physically addictive, causes physiological damage, and rarely allows spiritual growth
or personal insights and knowledge. Psychedelics, or entactogens (meaning “touching within”),
could be considered completely opposite, filled with potential for relieving anxiety, depression,
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addiction, or simply a more integrated, vital life (Schuster, 2013). Pharmacologist, David
Nichols (1986) coined the term “entactogen,” in describing MDMA’s therapeutic quality:
The idea of a therapy using one of these drugs, which is a totally new class of
drugs or psychotherapeutic adjuncts,…is using a drug which specifically allows
for the opening of certain kinds of communication. Above all, a good entactogen,
especially MDMA…appears in most cases to eliminate the very deep fear of
remembering trauma, of bringing up things which are tremendously painful and
very frightening and full of rage and grief. And in some way we have no way of
understanding, MDMA makes it possible for a patient to stop being afraid of the
things coming back to the conscious mind. They are able to elicit very buried
memories of difficult and painful things which need to be unburied.
There is not sufficient evidence to support the popular notion that the risks of adverse
effects are too high to utilize psychedelic-enhanced psychotherapy and treatment. There has been
research that shows that people with latent psychosis or genetic predispositions towards
psychosis should not explore psychotropic medication. However, researcher Rick Strassman
(1984) shows that the adverse effects and side effects are otherwise “subtle or nonsignificant.”
Brain damage is minimal, especially compared with alcohol or addictive substances (1984).
Moreover, if there are any negative affect or feelings experienced while on the drug, they tend to
be short lived and are nonpermanent in nature (1984).
So far, the statistical significance of psychedelic research has been astounding. Now that
research on psychedelic drugs faces fewer obstacles, the current study seeks to add to its
renaissance, discover more about therapeutic qualities of psychedelics, and promote safety
around use. The following research summaries and assessments suggest the necessity to support
further research of psychedelic psychotherapy. The current study focuses specifically on the
participants’ experience of treatment in the recent Phase 2 clinical trials investigating MDMAassisted psychotherapy for treatment-resistant PTSD and explores the correlation between
participants’ mystical experiences on the drug and long-term treatment outcomes.
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Study participants included seventeen subjects selected from the Multidisciplinary
Association for Psychedelic Studies (MAPS) sponsored Phase 2 investigation, A Randomized,
Triple-Blind Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in conjunction with
manualized psychotherapy in 24 Veterans, Firefighters, and Police Officers with Chronic,
Treatment-resistant Posttraumatic Stress Disorder (PTSD). The present study is comprised of a
subset of seventeen of the twenty-four participants who gave consent to be interviewed during
their one-year follow-up procedure post-treatment and to have their interview used in a
subsequent qualitative analysis. This study used a qualitative study design, interpretive
phenomenological analysis (IPA), in order to blend the participants’ vital personal experiences
with acquired statistical data to gain further understanding on the therapeutic usages of MDMA
on treatment-resistant PTSD, and long-term treatment outcomes. This study was based on the
assumption that hallucinogenic or psychedelic drugs such as lysergic acid diethylamide (LSD),
psilocybin, ayahuasca, and ±3,4-methylenedioxymethamphetamine (MDMA) are effective
measures to treat pervasive mental health disorders.
MAPS is a U.S.-based non-profit research and educational organization supporting
research of the therapeutic potential of MDMA. MAPS is sponsoring clinical trials to test
medical uses of MDMA-assisted psychotherapy for patients with chronic disorders like PTSD,
social anxiety related to autism, pain and anxiety related to terminal illnesses and further
research into its potential for therapeutic applications.
The primary limitation to this study was the lack of control group for the follow-up
interviews. It would be ethically problematic under the National Social Work Code of Ethics and
American law to conduct a placebo control group over such a long period of time. Other
limitations also reflect the preliminary nature of this study. The sample was small (n=17) and
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homogenous, reflecting a largely Caucasian demographic (n=15). Factors that might impact the
effects of MDMA were not explored, such as genetic history, religious or spiritual affiliation, or
attachment style. Finally, though the basic dimensions of the MEQ30 were utilized, shortening
the initial 100-item questionnaire (SOCQ-100) may have impacted our capacity to obtain more
nuanced information about psychoactive effects, particularly when comparing the difference in
dosage.
Chapter Two, which follows, provides a historical overview of MDMA and further
demonstrates that psychedelic treatment has data-driven potential for medical usage and low to
moderate risk for addiction. This chapter also defines PTSD and provides current available
treatment options and efficacies.
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CHAPTER II
Literature Review
This chapter informs the physiological and biological effects of MDMA on humans in
order to make the connection between the drug’s effects and how it constitutes change for people
struggling with PSTD. This includes a review of existing studies surrounding MDMA-assisted
psychotherapy to offer context for this research. A brief review of studies surrounding
psychedelic-enhanced therapies using other drugs follow in order to highlight the specific
usefulness of MDMA as compared to other hallucinogens.
History
Methylenedioxymethamphetamine was first synthesized and patented by the
pharmaceutical company Merck in 1912 (Freudenmann, 2006). There is no current patent today
on MDMA. Chemist Alexander Shulgin and his colleagues (1991) rediscovered MDMA in the
late 1970s and found that human emotions could be positively influenced by the entactogen
without experiencing adverse physiological or cognitive functioning. Shulgin (1991) also found,
similar to more current research, that MDMA increased feelings of closeness with other people,
feelings of wellbeing, and insightfulness. In 1985, MDMA was added to the category of
Schedule I controlled substances (CSA). Methodological limitations for studying this particular
drug, therefore, became difficult to overcome and research slowed to a standstill. Even today,
MDMA continues to be considered a Schedule I drug with no medical usage and high risk for
addiction, according to the CSA. MAPS (2013) explains the neurological effects of MDMA in
the 7th Edition of the Investigator’s Brochure:
MDMA is a ring-substituted phenethylamine that produces anxiolytic and
prosocial effects through release of the monoaminergic neurotransmitters with the
greatest effect on serotonin, followed by norepinephrine and dopamine. MDMA
has been shown to acutely decrease activity in the left amygdala and increase
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blood flow to the prefrontal cortex in the brain. MDMA has also been found to
increase serum levels of the neurohormones oxytocin and arginine vasopressin in
humans, which are likely to be involved in increased trust and attenuated
reactivity to threatening cues. The combined neurobiological effects of MDMA
can increase compassion for self and others, reduce defenses and fear of
emotional injury, while enhancing communication and capacity for introspection.
These factors taken together can provide the opportunity for a corrective
emotional experience in the context of psychotherapy. Many of the therapeutic
effects of MDMA-assisted psychotherapy are evident within a short period of
treatment, often after the initial session. Increased feelings of interpersonal
closeness, changes in social perception and reduced anxiety may make MDMA a
suitable pharmacological adjunct to enhance psychotherapy for anxiety disorders
such as PTSD and possibly social anxiety more generally.
The following literature review demonstrates that MDMA has data-driven potential for
medical usage and low to moderate risk for addiction. MDMA can provide a much-needed
option in the treatment of PTSD and other conditions associated with anxiety.
Posttraumatic Stress Disorder (PTSD)
DSM-IV-TR diagnostic criteria. The American Psychiatric Association (APA) asserts
in the text-revised, fifth edition of their Diagnostic and Statistical Manual of Mental Disorders
(DSM V-TR) that PTSD begins with the exposure to an extreme traumatic stressor (APA, 2013).
PTSD is an anxiety disorder with two main debilitating groups of symptoms. Primary PTSD
symptoms consist of re-experiencing, hyper-arousal, and avoidance symptoms; the second group
includes impaired functioning, poor coping skills, psychiatric and medical comorbidity,
suffering, drug abuse, and suicide risk (Cohen, Marmar, Ren, Bertenthal, & Seal, 2009; Kessler,
Chiu, Demler, Merikangas, & Walters, 2005; Kozarić-Kovačić, 2008; Mithoefer et al., 2010). In
spite of PTSD being a major world-wide health problem, psychotherapeutic and pharmacological
treatments for this chronic illness have shown to be only partially effective for most people
(Carr, 2011). While there is immense empirical literature on trauma, its treatment remains
elusive.
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Even 3,000 years ago, Homer (Fitzgerald, 1990) showed us that PTSD from combat
trauma can impact the health of a veteran’s psyche in the gruesome final chapter of the Odyssey,
Slaughter in Hall. Despite the popular notion that the soldier, Odysseus achieves his goal when
he arrives home in Ithaca, he is unable to integrate into society again, kills everyone in his home,
and departs for another journey. Homer offers us a metaphor for the difficulties of fostering a
healthy psychic life following a traumatic event (Shay, 2002). PTSD is still as pervasive and
unrelenting because existing treatments are not reliable or lasting for the majority of people
suffering from this disease. Even therapies with the most empirical support, like CognitiveBehavioral Therapy (CBT), tend to show drop-out rates of up to 54% and nonresponse rates of
up to 50% (Schottenbauer, Glass, Arnkoff, Tendick, & Gray, 2008). These forms of CBT
currently have the most evidence for efficacy (Carr, 2011). While there is also evidence that
pharmacotherapy and psychotherapy utilized in conjunction to treat PTSD leads to increased
success rates, there are currently no manualized or legal therapies that offer such a reliable model
(Hetrick, S., Purcell, R., Garner, B., & Parslow, R., 2010; Mithoefer et al., 2012).
What is in fact known, however, is that talking about the trauma in a safe environment
and emotionally stable state is healing both physiologically and psychologically. Elizabeth
Maynard Schaefer (2008) explains how not talking about a trauma can lead to more debilitating
symptoms and illnesses:
Psychological researchers have long known that traumas or significant emotional
crises are stressful to the mind and body. This effect is so dramatic that
traumatized people have higher rates of depression and other ailments and are
even more likely to die of cancer and heart disease than that general population.
What is it about these traumas that leads to such health problems? In the 1980s,
researcher James W. Pennebaker (now at the University of Texas at Austin) and
his team found a clue. They studied people who had experienced a life-changing
trauma in childhood such as the death of a family member, the divorce of parents,
physical abuse, or a sexual trauma. They discovered that people who had such an
experience but kept it secret were at much higher risk for both major and minor
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illnesses than those who spoke about it. Their different levels of health were easy
to discern: the secret-keepers went to the doctor 40% more often.
PTSD appears to be so difficult to overcome because trauma can be incredibly hard to
talk about. Symptoms of dissociation, hyper-vigilance, and re-experiencing all promote
avoidance and therefore a roadblock to healing. As the following literature shows, MDMA has
the potential to help people feel able to safely confront and hence work through their trauma.
Existing treatments for PTSD. Cognitive behavioral therapies, particularly prolonged
exposure and cognitive processing therapy, are considered among the most effective
psychotherapies for treatment of PTSD. Psychodynamic therapy and eye movement
desensitization and reprocessing (EMDR) have also proven to be effective in treating some
symptoms of PTSD (Ursano, 2004). Because of the enduring effect of PTSD, many people
undergo more than one treatment to reduce or resolve PTSD symptoms (Hamner, Robert, &
Frueh, 2004). A recent meta-analysis concluded that all accepted, evidence-based
psychotherapies, including those listed above, are similarly effective for PTSD and have an
average effect size of 0.25 (Benish, Imel, & Wampold, 2008). While a wide variety of treatments
exist for PTSD, most have shown limited efficacy. The majority of accepted treatments benefit
just a portion of the population or bring relief to a limited number of symptoms while bringing
about difficult side effects that further lower quality of life (Foa et al., 2009; Kar, 2011;
Mitheofer et al. 2010; Stein, 2009).
MDMA
Over two decades after the illegalization and criminalization of MDMA, Mithoefer,
M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., & Doblin, R. (2010) completed the first
clinical trial evaluating MDMA as a therapeutic adjunct. Twenty subjects with treatmentresistant PTSD were randomly assigned to concomitant active MDMA (n=12) or inactive
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placebo (n=8). The study utilized the Clinician Administered PTSD Scale (CAPS) as the
outcome measure administered at baseline, 4 days after each experimental session, and 2 months
after the second session. The rate of clinical change from baseline was significantly higher in the
active dose group (83%) compared to the placebo group (25%). There were no serious adverse
events related to MDMA, adverse neurocognitive effects, nor significant blood pressure
increases. Mithoefer et al. (2010) shows initial efficacy and safety using MDMA-assisted
psychotherapy.
Mithoefer, M.C., Wagner, M.T., Mithoefer, A.T., Jerome, L., & Doblin, R. (2012) later
completed a follow-up study to investigate the lasting effects of the aforementioned 2010 study.
Using the Clinician-Administered PTSD Scale (CAPS), Impact of Events Scale-Revised, the
Neuroticism Extroversion Openness Personality Inventory-Revised, and a long-term follow-up
questionnaire (LTFU), the researchers found that on average subjects maintained statistically and
clinically significant improvements in symptom relief and reported no harm from participating in
the study. CAPS scores that were taken directly after treatment showed no significant difference
from the long-term scores taken on average 3.5 years after treatment. This pioneering study gave
the first evidence of enduring, clinically meaningful benefit of MDMA-assisted psychotherapy
for treatment-resistant PTSD. The LTFU also showed that no participant developed a problem
with any illicit substance after their MDMA-assisted psychotherapy, which supports the
hypothesis that MDMA can be administered in a regulated, clinical setting without creating a
dependence or addiction.
The Mystical Experience Questionnaire (MEQ30) measures unity, noetic quality,
sacredness, positive mood, transcendence of time/space, and ineffability (Maclean, Johnson,
Leoutsakos, & Griffiths, 2012). Participants in the current study completed the 100-item States
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of Consciousness Questionnaire (SOCQ-100) after each MDMA-assisted psychotherapy session.
The MEQ30 is comprised of 30 questions selected from the SOCQ-100. The research from
Maclean, Johnson, Leoutsakos, & Griffiths (2012) shows that the MEQ30 is a reliable and valid
measure that correlates with other mysticism scales, such as the Hood Mysticism Scale (Hood,
1977). This data may be biased towards positive experiences with psychedelics because the
participants self-selected into the study. Nonetheless, the data here support that the MEQ30 is a
useful tool in future scientific study of psychedelic experiences. This project will utilize data
from the MEQ30 in order to understand the correlation of mystical experiences with long term
MDMA-assisted treatment outcomes. This project will also utilize the outcome measure,
Clinician-Administered PTSD Scale (CAPS) in order to assess the long-term effects of MDMA
of PTSD. Blake, et. al, (1995) asserts that of all the structured diagnostic interviews available to
assess PTSD, CAPS appears to be the most reliable and valid in measuring the frequency and
intensity of each symptom.
Following the first investigations of the effects of MDMA on PTSD, researchers in
Switzerland tested the safety and efficacy of this treatment and found similarly hopeful results.
Oehen, Traber, Widmer, & Schnyder (2012) designed a randomized, double-blind, activeplacebo controlled trial enrolled 12 patients for treatment with either low-dose (25 mg, plus 12.5
mg supplemental dose) or full-dose MDMA (125 mg, plus 62.5 mg supplemental dose). MDMA
was administered during three experimental sessions and supplemented with weekly
psychotherapy sessions. The Clinician-Administered PTSD Scale (CAPS) and the Posttraumatic
Diagnostic Scale (PDS) were used as outcome measures. Patients were assessed at baseline,
three weeks after the second and third MDMA session (end of treatment), and at the 2-month and
1-year follow-ups. This study supported the hypothesis that MDMA-assisted psychotherapy can
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be safely administered in a clinical setting. No drug-related serious adverse events occurred and
there were no statistically significant reductions in CAPS scores (p = 0.066). However, there was
clinically and statistically significant self-reported (PDS) improvement (p = 0.014). Illuminating
the long-terms effects of MDMA-assisted psychotherapy, CAPS scores improved further at the
1-year follow-up. Additionally, researchers found that three MDMA sessions were more
effective than two (p = 0.016).
In 2008, some of the leading researchers in this field produced another study to show how
MDMA-assisted psychotherapy can help women with chronic post-traumatic stress disorder.
Bouso, Doblin, Farre, Alcazar, and Gomes-Jarabo (2008) tested different doses of MDMA with
women diagnosed with chronic PSTD stemming from sexual assault in a fully approved,
controlled study about safely administering MDMA. The study was meant to have 29
participants, but because of political reasons, it was shut down before more than six participants
could complete the trial. The study deemed MDMA safe for the six subjects. No participant
experienced an increase in symptoms on any of the psychopathological scales that were used and
all participants were entirely safe physiologically as well.
Since there is evidence that certain psychedelic drugs are safe physiologically,
neurologically, and psychologically, it is helpful to develop an understanding of their specific
therapeutic uses. Bedi, Phan, Angstadt, and de Wit (2009) studied the effects of MDMA on
sociability with regards to social threat and social reward. The researched compared fMRI
responses in participants’ brains to angry facial expressions, frightened facial expressions, and
happy expressions on placebo and on 1.5mg/kg of MDMA. They found that MDMA attenuated
amygdala responses in reaction to the threatening or angry face and heightened ventral striatum
responses in reaction to the happy face. In other words, subjects using the MDMA were less
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threatened by the angry face and happier in response to the happy face than those taking the
placebo. Interestingly, there was no difference in reaction to the fearful face in both control
groups. This study is important in understanding potential therapeutic uses as well as risks. In
chronic abuse situations, it is a useful protective strategy for victims to have a highly reactive
amygdala. However, if a person is no longer in danger, but suffering from PTSD, this study
shows that MDMA decreases perceptions of social threat, which could therefore assist in
relieving anxiety and stress.
In essence, because there are robust data that show psychedelics can be safe for humans,
the article by Dumont, Sweep, Van der Steen, Hermsen, Donders, and Touw et. al. (2009) that
seeks to explain why they may be useful therapeutically is the logical next step of exploration.
According to the article abstract, the researchers used a double blind, randomized, crossover, and
placebo-controlled study in 15 healthy volunteers in order to assess blood oxytocin and MDMA
concentrations as well as subjective prosocial effects and behavior. The study found that MDMA
increases oxytocin levels which, based on what we know about oxytocin, might be correlated
with the prosocial effects of the drug. The subjective accounts from the participants about their
prosocial feelings correlated with the amount of MDMA and oxytocin in their blood. Of course,
there is confounding bias in this study since the design cannot determine if the rise of oxytocin
caused the prosocial feelings. The study would have gained validity if a more objective measure
to study the prosocial effects was used. Instead of simply asking patients, the study suggests
utilizing measurable social games so that the participants not only perceive themselves as
friendlier, but also actually objectively act more socially.
There have also been useful studies solely involving self-reports of experiences under the
influence of MDMA. In 1997, Davidson & Parrott interviewed twenty recreational drug users,

19

asking them to describe the psychological and physiological effects they experienced under
MDMA. The subjects comprised 11 males and 9 females, 18-31 years old, who took MDMA
anywhere from 1-10 times. Each subject completed a modified Profile of Mood States
Questionnaire (POMS), an Ecstasy Effect Questionnaire, and a structured interview that included
questions about their past MDMA-use. Each participant reported increased feelings of elation,
agreeableness, energy, and mental confusion while they were on the drug. The subjects also
generally reported a faster heart rate, feeling hot, increased sweating and dehydration, dilated
pupils, and tight jaw. There was also a consensus that coming off of MDMA led to feelings of
lethargy, moodiness, insomnia, depression, irritability, and paranoia, which Davidson & Parrott
(1997) attribute to a possible reason why risk for addiction with MDMA is so low. Bad MDMA
trips were reported by 25% of the sample, following a variety of unpleasant experiences. An
increased tolerance was not apparent, although the regular users all described their first MDMA
experience as 'the most intense,' later trips were affected by knowledge and expectancy, rather
than any diminution in drug response.
Liechti, M., Gamma, A., Vollenweider, F., (2001) conducted a study on gender
differences in subjective effects of MDMA. Their work analyzed data from three different
controlled studies on the physiological and psychological effects of MDMA in a total of 74
healthy volunteers (54 male, 20 female). The research concluded that psychoactive effects of
MDMA tend to be more intense in female subjects than male subjects. Women had higher scores
for MDMA-induced perceptual changes, thought disturbances, a fear of loss of body control.
Moreover, the administered dose correlated positively with the intensity of perceptual changes in
women. Acute adverse effects were also more frequent in female subjects than male subjects.
However, the male subjects showed higher increases in blood pressure than woman. Equal doses
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of MDMA per kilogram of body weight was used to control for weight differences in males and
females. With this control, women showed stronger responses and increases in susceptibility
compared to men. It is important that researchers are aware that gender is related to susceptibility
differences when assigning appropriate dosages for future studies and therapies.
Other Psychedelics
We know that psilocybin mushrooms, ayahuasca, peyote, and other psychedelic plants
have been ingested by humans for thousands of years or religious or spiritual purposes. However,
we lack knowledge about the long-term effects of hallucinogens (Griffiths, Richards, Johnson,
McCann, & Jesse, 2008). The experiential differences of MDMA and other psychedelic
substances are important to explore in order to best utilize their capacities for particular mental
health problems. Griffiths, Richards, Johnson, McCann, and Jesse (2008) did a double-blind
study on the psychological effects of a high dose of psilocybin and enacted a follow-up study 14
months later in order to learn more about long-term effects. Of the 36 participants who had never
experienced any kind of hallucinogenic drug prior to the study, 67% rated that their psilocybinoccasioned experience was one of the five most personally meaningful and spiritually significant
experiences of their entire lives (2008). This study suggests that even 14 months later, mystical
experiences with psychedelic, also referred to as entheogenic, drugs can produce positive
changes in attitudes, mood, altruism, behavior and life satisfaction. This study used the PanhkeRichards Mystical Experience Questionnaire (MEQ30) in order to quantify mystical experience.
The reliability and validity of this questionnaire were explored by Thomas et al. (2013).
Thomas et al. (2013) found in a study on problematic substance use and stress that after
four days of group counseling and two ayahuasca-assisted therapy sessions, “improvements were
demonstrated for scales assessing hopefulness, empowerment, mindfulness, and quality of life
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meaning and outlook (Thomas, Lucas, Capler, Tupper, & Martin, 2013, p. 1).” The findings
show that alcohol, cocaine, and tobacco use significantly declined and remained lower in a six
month follow-up. This study not only shows that ayahuasca can benefit people suffering from
particular addictions, but also shows that the mental and behavioral health issues coinciding with
the addiction subside. However, the study was limited in that it had no matched control groups
and lost touch with a few participants for the six-month follow-up.
Beyond qualitative reporting of the effectiveness of psychedelic psychotherapy, there has
been important research on the effects on the brain. Neuroscientists, Robin Carhart-Harris,
Kaelen, and Nutt (2014) led a study that observed the brain while on LSD. Through the first
modern neuroimaging of LSD, the researchers found significant correlative activity. CarhartHarris et al. (2014) found that the brain on LSD has “increased visual cortex CBF, RSFC, and
decreased alpha power, predicting the magnitude of visual hallucinations; and decreased DMN
integrity, correlating with profound changes in consciousness, typified by ego-dissolution
(Carhart-Harris, Kaelen, & Nutt, 2014, p. 4856).” Essentially, this study shows, via neuroimages,
how hallucinogens profoundly affect brain function and, therefore, consciousness. Egodissolution, an integral feeling contributing the loss of a sense of self, is usually involved in
mystical experiences. This study sheds light on what occurs in the brain during consumption of a
psychedelic which aligns with qualitative reports of ego-dissolution and mystical experiences.
Scott Hill’s (2013) book, Confrontation with the Unconscious: Jungian Depth
Psychology and Psychedelic Experience, connects the latest scientific data with clinical practice.
Hill (2013) integrates Carl Jung’s theoretical orientation of archetypes, the collective
unconscious, and mysticism with psychedelic psychotherapy. The mythological and symbolic
similarities of Jung’s writing of the unconscious and images or feelings reported on
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hallucinogens deems further research on this comparison for legitimacy. One limitation Hill
(2013) presents is that Jung (1966) himself was relatively opposed to hallucinogenic-enhanced
paths to unconscious material. With reason, Jung wrote about the risks involved in ignoring the
natural defenses humans put in place in order to restrict access to the depths of our psyches that
psychedelics bring us. Jung (1966) believed in the transformative power of confrontation with
the darkest aspects of ourselves, but also believed getting there too fast could be destructive.
Therefore, the way in which practitioners help their clients prepare for and then integrate their
experiences on hallucinogens seems particularly important.
A study by Maclean, Johnson, and Griffiths (2011) showed that personality change in
adults is possible following a high-dose psilocybin session. The researchers tested five domains
of personality -- neuroticism, extroversion, openness, agreeableness, and conscientiousness -- to
find that openness was statistically significantly increased and stayed increased over one year
after the trial. This study shows that effects of high-dose psilocybin can be measurable and
lasting using double-blind, controlled methods. They also explored the concept of mysticalexperiences-- “feelings of unity and interconnectedness with all people and things, a sense of
sacredness, feelings of peace and joy, a sense of transcending normal time and space,
ineffability, and an intuitive belief that the experience is a source of objective truth about the
nature of reality” (p. 2). This experience led participants to experience lasting and beneficial
personality change. Maclean, Johnson, and Griffiths (2011) include helpful subjective reports as
well, which show that 50-80% of participants felt lasting changes in values, personality,
attitudes, and behavior.
Peter Gable, a psychology professor at the Claremont Graduate School, provides
additional psychedelic literature. He describes his personal experience using psilocybin and his
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conversations with both Skinner and Maslow around his experience. One of the most important
anecdotes is Gable’s claim that ingesting psilocybin mushrooms has helped him communicate
with his terminally ill patients in the hospice where he worked. Skinner responded to Gable
regarding psilocybin, “We may have been able to make the same change by manipulating
standard environment variables; the drug now permits us to circumvent that manipulation” (p.
45). The original behaviorist may have been interested in helping people make changes when
their environment or situation is unchangeable with the assistance of psychedelic-assisted
therapy.
Finally, Gasser, Kirchner, and Passie (2015) published an important study on the safety
and efficacy of LSD-assisted psychotherapy in patients with existential anxiety induced by a lifethreatening disease. One year after completing LSD-assisted psychotherapy, 10 participants were
tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content
Analysis (QCA) was conducted on the interviews to elaborate about LSD effects and lasting
psychological changes. Improvements measured by the STAI were sustained over the year
showing that the changes are long lasting. Subjects consistently reported insightful, cathartic and
interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of
life (66.7%) in the QCA. These reported experiences helped restructure the participants’
emotional trust, situational understanding, habits, and worldview. No lasting adverse reactions
were reported by any of the participants. This study is particularly useful because it highlights
the importance of collecting qualitative data in order to understand subjective reports of efficacy
and sustainability.
The most compelling purpose in investigating psychedelic psychotherapy is to learn more
about the efficacy of treatment and how it is being facilitated. If the opportunity exists to use new
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treatments to relieve human suffering, then it must be explored. This is particularly true when
current medication and treatment options are minimal and unreliable for a vast amount of people.
While we now know that this type of therapy can be safe and effective, the existing literature
reveals a knowledge gap in the understanding of long-term effects of psychedelic-assisted
therapy.
Summary
Existing treatments for the destructive disease, PTSD, are not adequate in providing
lasting help for a significant number of traumatized people. Based on what is known about the
effects of MDMA on humans, there is reason to explore how this psychedelic can promote
therapeutic action and lasting symptom improvements. The current study aims to address the
lacuna in the existing literature by investigating the correlation between mystical experiences and
long-term MDMA-assisted treatment outcomes on treatment-resistant PTSD. Ultimately,
learning about what makes psychedelic psychotherapy therapeutic and meaningful may reveal
roadblocks and direction for future safe and useful treatments. Current data are thin regarding
what specific experiences or feelings within a psychedelic treatment cause therapeutic action.
The current study specifically explores the correlation of MEQ30 scores with CAP scores and
data from participants’ LTFU interviews as outcome measures. Information on demographics
may be informative about who this therapy is available to and for whom it works or does not
work.
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Chapter III
Methodology
Research Design
A wealth of both quantitative data and qualitative data on the therapeutic use of
psychedelics is available. Historically, personal accounts of mystical experiences while under the
influence of psychedelics show that these drugs can increase insightfulness, acceptance, and
empathy. Lately, research has taken a more quantitative turn that shows that the personal
descriptions align with the science. The current study blends vital personal experiences with the
necessary statistical data in order to shed light on the therapeutic usages of MDMA on treatmentresistant PTSD, and long-term treatment outcomes. The methodological framework of the
current study is Interpersonal Phenomenological Analysis (IPA) and includes detailed analysis of
participants’ personal accounts followed by a presentation and discussion of experiential themes
in order to make meaning of the participants’ experiences with MDMA-assisted therapy
(Pietkiewicz, I. & Smith, J., 2012).
To provide this qualitative perspective, analysis focuses on participants’ one-year followup LTFU interviews. These interviews were designed to investigate participants’ experience with
MDMA-assisted treatment, how they have felt it has or has not led to changes in symptomology
in their life, suggestions for changes to benefit the study protocol, substance use changes,
differences in interpersonal relationships, and a variety of other topics. The analyses of these
qualitative interviews focus on interview transcripts and are considered with other quantitative
data sources including pre and post-therapy CAPS scores, measuring symptom severity and
MEQ30 scores, a measure of alterations in consciousness related to mystical experiences.
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Additional insight about study effectiveness and protocol is expected, potentially lending
to the development of a treatment that can reach a wider variety of people in need. Finally, these
data serve as a foundation to discuss a theory for how the neurochemical actions of MDMA work
in the context of therapeutic action for posttraumatic stress disorder.
Qualitative Methodology
Interpretative Phenomenological Analysis (IPA). Biggerstaff and Thompson (2008)
refer to IPA as a qualitative methodology that “can offer as a research tool in understanding
healthcare and illness from the patient or service user perspective” (p.2). IPA supplements other
traditional qualitative methods in using an idiographic component to analysis in addition to the
standard phenomenology and hermeneutic practices of other methods (Smith, Flowers & Larkin,
2013). This allows researchers to look beyond the simple “what” and “how” of participants’
experiences towards the meaning behind their experiences. Smith & Osborn (2003) explain that
the purpose of using IPA is simply “to explore in detail how participants are making sense of
their personal and social world” (pg. 53). The primary attribute for an IPA study is the meaning
specific experiences, events, or self-states hold for participants (Smith & Osborn, 2003). Finally,
IPA was chosen as the methodology for this study because it has been the primary methodology
in similar qualitative investigations into MAPS sponsored studies. For example, the MAPS
sponsored New York University study of psilocybin-assisted psychotherapy for end-of-life
anxiety used IPA to explore the safety and efficacy of this psychedelic-assisted treatment. Using
IPA in this qualitative analysis will help to further evaluate its usefulness in the field of
psychedelic study.
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Sample
Inclusion criteria. Subjects are men or women aged 18 or older with a confirmed
diagnosis of chronic, treatment-resistant PTSD who have undergone psychotherapeutic or
psychopharmacological treatment for PTSD of adequate dose/duration without achieving
remission. All participants in these samples were in the severe category of symptoms as outlined
by results on the CAPS as well as deemed treatment resistant by unsuccessful psychotherapy or
pharmacological treatments (Mithoefer et al, 2010; Mithoefer et al, 2012). Mean baseline CAPS
scores (84.7) indicated extreme chronic PTSD with an average duration of 17.8 years. Subjects
who discontinued PTSD treatment due to inability to tolerate psychotherapy (e.g. due to
persistent “over-engagement”) or psychopharmacology due to treatment-emergent side effects
were not excluded. Subjects were not excluded for having more than one traumatic event.
Subjects had a last month CAPS score equal to or greater than 50 and are in good physical health
and without major medical disorders that might affect the safety or tolerability of MDMA were
eligible for study inclusion.
Exclusion criteria. Criterion which would have excluded participants from taking part in
the Phase 2 trials mainly describe conditions that would put the participant or others in danger, or
would drastically confound data from their participation. These criteria can be found in the
original MAPS Investigators Brochure (2010) which excludes participants that:
1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an
effective means of birth control;
2. Have a history of, or a current primary psychotic disorder, bipolar affective disorder type 1 or,
dissociative identity disorder;
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3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease,
hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the
investigator to significantly increase the risk of MDMA administration;
4. Have hypertension using the standard criteria of the American Heart Association (values of
140/90 or higher assessed on three separate occasions [72]), unless their hypertension has been
successfully treated and is currently well-controlled on antihypertensive medicines. In this case
subjects with well-controlled hypertension were enrolled if they passed additional screening to
rule out underlying cardiovascular disease;
5. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have
undergone additional evaluation. Subjects with Hepatitis C were enrolled if they received
appropriate screening;
6. Have history of hyponatremia or hyperthermia;
7. Weigh less than 48 kg;
8. Would present a serious suicide risk, as determined through psychiatric interview, responses to
C-SSRS and through the clinical judgment of the investigator, or who, in the judgment of the
investigator, are likely to require hospitalization during the course of the study;
9. Would present a serious risk to others as established through clinical interview and contact
with treating psychiatrist;
10. Have used “Ecstasy” (material represented as containing MDMA) more than five times
within the last 10 years or at least once within 6 months of the MDMA session;
11. Require ongoing concomitant therapy with a psychotropic drug;
12. Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for substance
abuse or dependence for any substance save caffeine or nicotine in the past 60 days;
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13. Are not able to give adequate informed consent;
14. Have any current problem or a history of substance abuse which, in the opinion of the
investigator or medical monitor, might interfere with participation in the protocol.
Sample characteristics. The sample of the current study includes 17 subjects. 15
participants identified as White/Caucasian and 2 identified as Native American. 12 participants
identified as male and 5 as female. At baseline, participants ranged in age from 24 years to 56
years (6 were 20-30 years old, 5 were 31-40 years old, 4 were 41-50 years old, and 2 were 51-60
years old).
Recruitment procedures. Participants were recruited via letters of referral sent to
psychiatrists and psychotherapists, contact with veterans’ organizations, written advertisements,
announcements placed on appropriate internet sites and the sponsor website, and word of mouth.
Candidates could also be individuals who had previously contacted the investigators expressing
interest in taking part in the initial study of MDMA-assisted psychotherapy for PTSD after that
study had closed enrollment.
One of the investigators or their assistant interviewed prospective participants by
telephone to learn if they met basic eligibility criteria. If the prospective participant was
interested in taking part in the study, the investigators provided her or him with consent materials
for review and consideration through postal mail or electronically. If, after review, a potential
participant remained interested in taking part in the study, then he or she met with the
investigators to complete the consent process. Participants completed a quiz to assess their
understanding of the consent forms. Investigators reviewed the quiz responses with the
prospective participant to ensure that he or she correctly understood study procedures, risks and
benefits.
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Data Collection
Data was comprised from secondary data from MAPS (2016) study, “A Randomized,
Triple-Blind Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in conjunction with
manualized psychotherapy in 24 Veterans, Firefighters, and Police Officers with Chronic,
Treatment-resistant Posttraumatic Stress Disorder (PTSD)” in the form of transcriptions of
qualitative interviews one year following the treatment, long-term follow-up questionnaires,
MEQ30 scores taken between the end of each MDMA-assisted psychotherapy session and before
they left the treatment facility the next day, and CAPS scores from before and after treatment.
Measures
The CAPS is the primary outcome measure that determines PTSD symptom severity. The
CAPS yields a global symptom severity score, as well as a categorical ranking as to whether or
not a subject meets DSM-IV-R criteria (American Psychiatric Association, 2000) for PTSD
diagnosis (Weathers et al., 2001; Blake et al., 1995). The current study utilized pre and posttreatment CAPS scores in order to compare PTSD symptom severity before and after treatment.
The LTFU questionnaire is designed to capture the perceived benefit or harm of MDMAassisted psychotherapy and changes in any areas not addressed by standard outcome measures,
such as changes in relationships or creativity. The questionnaire measures the degree (with an
ordinal scale of 1-Slight to 5-Large) and persistence (scale of 1-Small to 5-All) of the perceived
benefits and/or harms of MDMA-assisted psychotherapy for PTSD (Mithoefer, 2012).
Additionally, the questionnaire includes items addressing participant beliefs concerning the
potential benefit of receiving an additional MDMA- assisted psychotherapy session, any
psychiatric treatment after the study (whether psychotherapy or psychiatric medications), and
their use of “ecstasy” (material represented as containing MDMA) and/or any other illicit
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psychoactive substances after study participation, plus any perceived changes in cognition after
study participation. The participants were invited to write comments relating to their
participation in the study. The full questionnaire is available online (MAPS, 2009) as
supplemental material.
In conjunction with the questionnaire, subjects completed a dynamic, verbally-performed
and video-recorded, semi-structured LFTU interview one year following treatment. Therapists of
the Phase 2 clinical trials, Michael and Annie Mithoefer facilitated the interviews. A Long-Term
Follow-Up Qualitative Interview Guide was created by the research team of the current study in
accordance with the practices of IPA to lead the interviewers to gain pertinent data for analysis
throughout the interview (Smith, 2004). This interview guide includes subjects such as
participant perceptions on benefit of study participation, harm of study participation, helpfulness
of an additional MDMA-assisted session, and perception of therapy prior to and after the study.
This interview guide also aims to gain any information on psychiatric medication use before and
after the study, any use of MDMA/ecstasy before or after the study, non-prescription substance
use before and after the study, information on any significantly stressful events since study
completion, subject requests, and other pertinent information.
Participants completed the SOCQ100, a 100-item questionnaire measuring the
dimensions of classic mystical experience: unity, noetic quality, sacredness, positive mood,
transcendence of time/space, and ineffability directly after each MDMA-assisted psychotherapy
session. Maclean, Leoustakos, Johnson, & Griffiths (2012) researched the efficacy of the
SOCQ100 and found that 30 items alone effectively measure mystical experience. The current
study utilized the 30 items from the SOCQ100 that constitute the MEQ30. The MEQ30 is a selfreport measure that has been used to study the effects of hallucinogens in laboratory studies
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(Maclean, Leoustakos, Johnson, & Griffiths, 2012). Each item was rated on a 5-point scale
(0=none, not at all; 1=so slight cannot decide; 2=slight; 3=moderate; 4=strong [equivalent in
degree to any previous strong experience]; and 5=extreme [more than ever before in my life and
stronger than 4]).
Participation
Risks of participation. While serious MDMA toxicity is rare even in uncontrolled or
recreational settings, there were some risks involved in participating in this study. Although no
participant reported adverse effects in the current study, some associated rare negative
physiological effects can be hyperthermic syndromes, dysphoria, panic or psychotic response,
hepatotoxicity, and hyponatremia (Downing, 1986). The majority of hospital visits related to
MDMA or ecstasy use occur because of anxiety or panic attacks. Anxiety or distress during the
MDMA session could last anywhere from 15 minutes to 5 hours, according to Phase 1 MDMAassisted psychotherapy research (MAPS, 2013). Moreover, psychological distress could arise
following an MDMA session as a result of participants having difficulty integrating their
experience after the effects of MDMA have subsided. Fatigue, feeling anxious or weak, or
experiencing low mood are occasionally reported up to three days after MDMA administration
(1986). Participants were also expected to experience significant, but transient increases in heart
rate and blood pressure. In the current study, participants were informed that experimental
sessions have the intention of confronting and working through traumatic experiences.
Therefore, psychological distress, anxiety, or other unpleasant psychological reactions were
generally expected and considered important aspects of the therapeutic process (MAPS, 2016).
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Benefits of participation. Participants who chose to engage in the current study were
people who attempted at least one other type of treatment to relieve their symptoms of PTSD.
Because no other treatment proved efficacious or lasting improvement for these participants,
they had few alternative options for getting help and showed potential to benefit from this new
treatment. Subjects have categorized their benefit of the treatment in the long-term follow-up
questionnaire as, “benefit has lasted and continued to grow” (n=9), “virtually all benefit has
lasted” (n=3), or “most, but not all of the benefit has lasted” (n=3). Participants more specifically
labeled their benefit types as, “increased general wellbeing” (n=14), “increased ability to feel
emotions” (n=13), “less avoidance of people or places” (n=11), “improved sleep” (n=11),
“improved relationships with spouse, partner, or family members” (n=12), “improved
relationships in general” (n=11), “enhanced spiritual life” (n=10), “increased self-awareness or
understanding” (n=14), “increased creativity” (n=7), “increased empathy for others” (n=11),
“more involved in the community or world” (n=10), “fewer nightmares, flashbacks, or intrusive
memories” (n=12), “reduced anxiety” (n=12), “less excessive vigilance” (n=11), “improved
work performance” (n=9), “improved mood” (n=10), and “other psychological benefit” (n=8).
Informed consent procedure. The informed consent form (ICF) was signed and dated
by the participant and countersigned by the investigator. The investigator provided a copy of the
signed ICF to the subject, and maintained the original in the investigator’s study file. See
Informed Consent Form in Appendix A.
Written consent to take part in the study session included giving the investigators
permission to view the participant's recent medical records to assess protocol eligibility, if
needed. Information necessary for protocol participation included past medical history,
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psychiatric interview, physical examination, and clinical laboratory tests. Participants could
withdraw consent for their participation in the protocol at any time without prejudice.
Confidentially and anonymity. Every effort was made to strictly safeguard the
confidentiality of participants in their role as research participants. MAPS removed identifying
information from data and restricted access only to researchers directly involved in assessing the
participants, preventing the dissemination of confidential data. The informed consent and a
subject contact information sheet were stored separately from other documents. All data was
identified only by the participant's initials on the source document and four- digit subject
number. If past medical records were required, participants signed forms for the release of
information upon consent to permit screening for protocol enrollment. Copies of audio and video
recordings intended for sharing with participants were marked only with the participant’s subject
number. Any materials mailed to participants were sent along with stamped return envelopes
using the office address of the Clinical Investigator both as main and return address. All
assessment records were kept in a locked file drawer or cabinet in a locked office, and access to
measures were limited to regulatory agencies, researchers, and individuals analyzing data.
Researchers, other than the investigators directly involved in the protocol, with access to data
were not provided with any information that would identify participants by name or by other
means, such as social security number.
All psychotherapy sessions were video and audio recorded. These recordings were used
for manual development and may potentially be used for training therapists to perform MDMAassisted psychotherapy. Full names and addresses do not appear in these recordings.
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Any use of recordings for purposes other than research or training (e.g. a documentary
film) may occur only with separate written informed consent of the participant obtained after
study participation is complete.
Maintaining data in a secure environment ensured the prevention of the accidental or
deliberate examination or removal of data by unauthorized persons. While it is possible that
individuals may be identified on audiotape or video recording through means other than their
names, restricting access to audio recordings or video recordings to researchers or trainees
greatly reduced the risk of a breach of confidentiality.
Human Subjects Review Board. This study was reviewed and approved by the
Copernicus Group, the Institutional Review Board of record, and received exemption from Smith
College School for Social Work based upon the Copernicus Group’s approval. See Human
Subjects Review Board approval letter in Appendix B.
Voluntary nature of participation. Participants volunteered for the sessions with the
intention of confronting and working through traumatic experiences. Consent forms were
provided by the primary investigators describing the participants’ complete voluntary
involvement and choice to end participation at any point in the study.
Data Analysis
A computer-assisted qualitative data analysis software package, ATLAS.ti, was utilized
to assist in data analysis of the interview transcripts. Both individually and with committee
members, interviews were coded for content, emerging themes were identified, and data was
organized into thematic constructs utilizing a content analysis approach. A Pearson correlation
analysis was run in order to determine linear dependence of mystical experience scores and longterm symptom change.

36

CHAPTER IV
Findings
The current study was an interpretive phenomenological analysis (IPA) that used a
qualitative method design and a non-random purposive sampling method. The purpose of this
study was to investigate if mystical experience constitutes therapeutic change in MDMA-assisted
psychotherapy. By long-term follow-up (at least 12 months following the final MDMA session)
the overall remission rate was 66.2%, with an average drop of 47.7 points on the CAPS or mean
percentage improvement of 43.24%. The potential for MDMA-assisted psychotherapy to benefit
participants with treatment-resistant PTSD is clear by these measures. However, the current
study shows that mystical experience is not necessarily the therapeutic change agent for
participants in the Phase 2 clinical trials.
This chapter contains summaries of the quantitative data, including CAPS scores and
mean mystical experience scores, as well as qualitative data from long-term follow up interviews
completed 12 months after treatment. Some observations and inferences can be made for further
exploration and are described in the discussion chapter.
Quantitative Data
Table 1 shows that Pearson correlations between mean MEQ30 scores and long-term
positive symptom change codes (Sx+(LT)) are not statistically significant (r=0.171, p=0.512).
from their 12-month (long-term) symptom change codes. This suggests that MEQ30 scores of
assisted psychotherapy and long-term positive symptom change codes (Sx+(LT)) as reported in
LTFU interviews were not significantly different, and did not reach statistical significance.
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Table 1: Correlations between mean MEQ30 scores and Sx+(LT) codes as reported in LTFU
Interviews

Sx+(LT)

Mean MEQ30
Scores

Sx+(LT)
1

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)

17
0.171
0.512

N

Mean MEQ30
Scores
0.171
0.512
17
1

17

17

The following figure shows individual experimental data of participants’ MEQ30 scores
in relation to the number of instances Sx+(LT) was mentioned during LTFU interviews. There
was no correlation between MEQ30 and Sx+(LT) codes (r=0.171, p=0.512).
Figure 1: Sx+(LT) as reported in LTFU interviews as a function of mystical experience during
the active-dose MDMA session (n=17).
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Table 2 shows that Pearson correlations between mean MEQ30 scores and CAPS score
percentage improvement also are not statistically significant (r=-0.036, p=0.890).
Table 2: Correlations between mean mystical experience scores and CAPS Percentage
Improvement from baseline and year-long follow up assessments

CAPS %
Improvement
Mean MEQ30
Scores

CAPS %
Improvement
1

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

17
-0.036
0.890
17

Mean MEQ30
Scores
-0.036
0.890
17
1
17

The following figure presents the relationship between MEQ30 scores and CAP score
percentage improvement. Data points show individual experimental data. No significant
correlation between MEQ30 and CAPS improvement was found (r=-0.036, p=0.890).
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Figure 2. CAP score percentage improvement as reported by baseline and year-long follow up
assessments as a function of mystical experience during the active-dose MDMA session (n=17).

Qualitative Data
This section presents the findings of a qualitative analysis of participants’ experiences
with MDMA-assisted psychotherapy as reported in their LTFU interviews. In accordance with
the practices of IPA, the findings have been collected from a recorded interview in which each
participant discussed their experiences with the treatment, participant perceptions on benefit of
study participation, harm of study participation, helpfulness of an additional MDMA-assisted
session, and perception of therapy prior to and after the study. LTFU interviews also gained
information on psychiatric medication use before and after the study, any use of MDMA/ecstasy
before or after the study, non-prescription substance use before and after the study, information
on any significantly stressful events since study completion, symptom change, relationship
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changes, and other pertinent information. The qualitative data analysis is organized in the
following eight sections: (1) Enhanced quality of life (2) Reduction in negative PTSD-related
symptoms; (3) Reduction of illicit or harmful substance use; (4) Relationship improvement; (5)
Taking positive action or enacting lessons in life; (6) Improvement in self-awareness; (7) Overall
experience with the study; and (8) Subject recommendations.
Enhanced quality of life. All participants (n=17) reported enhanced quality of life after
completing the study. The following are quotes from LTFU interviews in which participants
address the benefit and general improvement in their wellbeing and quality of life from
participating in the study.
“There is improvement from every one of my problems I had when I first came
here.”
“Now I do feel hopeful and… it’s just this feeling that things are going to get
better. There’s going to be some time but it’s going to get better and better and
better. I don’t know where it will go but the PTSD is manageable.”
“I don’t worry about things as much as I used to, I just don’t. I don’t feel I need
to always carry a gun with me. I’ve come to the conclusion that I think I’m easygoing and well-mannered enough now to talk to people and talk myself out of
most situations now. I don’t have to fight. if I think back, I think that I did feel
that I needed to fight all the time before.”
“Now I actually live life and you know, I'm not living it for somebody else. I'm
living it for myself”
“This study has worked out well. My life has improved. Night and day, quite
dramatic.”
“I enjoy life, whereas before... Before I didn't care if I woke up or not.”
“I think that getting rid of all the, all the obstacles as far as my, my psychological
type of things, it was nice to be able to get that out of the way so I can focus on
actually improving my life. Which I think I've done quite, quite well here.”
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Reduction in negative PTSD-related symptoms. Nearly all participants (n=16)
discussed their improvement in symptoms following treatment during LTFU interviews. Some
quotes from the interviews are:
“It was really that first MDMA session that we had, where I had that I consider a
breakthrough. Where I was able to clearly see that I had a big disconnect in
compassion that I had for myself. After that first session, when I kind had that
epiphany, I was able to get sleep. I don’t stay up until 5 or 6 in the morning
anymore, unless I want to. It’s great.”
“I don’t feel as numb towards things. Prior to meeting y’all, I didn’t feel anything,
literally. I didn’t feel anything. Happy, sad, mad, I just didn’t feel anything. I’m
still somewhat numb about things but it’s not like it was.”
“The dreams that I am having are better, normal dreams, not terrors basically all
the time, waking me up every night. That's a lot better. That's probably the most
significant. And then that helps with stress, getting sleep.”
“There are a lot less fewer nightmares. I haven't hardly had any flashbacks. The
memories still pop up but they're not as distressing. I understand where they come
from.”
“If someone comes up and touches me, like behind me, before I would jump with
hypervigilance; I don't have that at all.”
Reduction of illicit or prescribed substance use. Existing research shows us that
MDMA has potential to treat neuropharmacological abnormalities associated with addiction and
could help provide a greater opportunity to address dangerous or unhealthy substance use
(Jerome, Schuster, Yazar-Klosinski, 2013). The following are quotes that support this hypothesis
by demonstrating how participants’ substance use was impacted after treatment.
“I've started learning the tools to where I don't need to depend or rely upon
medicine or alcohol or any kind of or even deviant behavior to feel better or get
through things and things like that. So I think that's been the most valuable.”
“When I first started I was taking 10 different things. And now no blood pressure
medicine, no anxiety pills, no pain pills.”
“I would drink and find out I didn’t have enough to try and get rid of (the
symptoms), but now I find out it just makes it worse.”
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“I think that’s what pushed me away from the alcohol was that the MDMA
proved to me that if you want something to help you it helps you continuously,
not just for a moment and then the next moment you are feeling bad. The study
helped me see that.”
“Before it was 15-20 drinks. And now it's down to three a week. I viewed
drinking as a really cool thing to do anytime you didn't have anything else to do.
It was just kind of this change of opinion of how I wanted to spend my time. I felt
like a need to drink a lot. I just don't feel that anymore.”
“I would easily go through probably an eighth ever two days, beforehand. Now an
eighth will last me two weeks.”
“I’ve come off all medicines. I’m on no kind of psycho medicine or anxiety
medicine or anything.”
Relationship improvement. The majority of participants (n=12) also benefited by
improving relationships with others in their lives following treatment in the study. While some
participants experienced confounding variables during the LTFU interviews, such as going
through a divorce, most reported a steady improvement in most aspects of their relationships as
reported in the following quotes.
“It’s crazy. It’s changed every dynamic of my life. Every relationship. That
means something to me… I couldn’t imagine this change. I didn’t think it was
possible.”
“My ability to talk with my family and relax with them and be and be able to do
things with them increased, and the communication. That was a positive thing that
came from the study.”
“(I feel) love, compassion, and it’s not just for family, it’s for everyone. My
parents and I have a much better relationship now, no doubt. But it goes beyond
family like if I see someone on the side of the road begging for money, I stop and
give them money even if I have to stop and hold up traffic behind me, I will do it.
The study helped me really get there.”
“My wife and I are getting a long a little better, talking about things more. So it's
helped a lot.”
“I think I've improved my own personal relationship with myself.”
“I truly believe if I hadn't been in this study, I would have never even been able
to, we would have, the relationship would have never even happened”
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“I would say overall improved relationships on every level, because before I
wasn't talking to my brothers, or my dad as often, and my family, and definitely
not my friends. I had really isolated.”
Taking positive action or enacting lessons in life. Nearly all participants (n=16)
reported in their LTFU interviews that they have become able to take healthy and rewarding
action in their life after the study. They also report enacting lessons learned during treatment
throughout life. The following quotes illuminate how participants have been able to concretely
make changes for themselves following treatment.
“It’s more of a, just relaxing in life. This whole thing allowed me to slow down
and enjoy, smell the roses instead of passing by the roses.”
“It changed my life...I mean I wouldn't be doing any of this stuff I'm doing now if
it weren't for the study.”
“I’ve caught myself many times over the past year feeling things rise up in me
like a bubbling teapot of, of emotion and actually physically saying to myself
“OK just feel it, just feel it.”
“It made me, actually, want to go pursue these other things that before I had
disregarded as possibly being helpful. And it made me actively pursue ‘em, on my
own, to see it if I could get the benefit from ‘em.”
“I've done some really weird and amazing shit since I've come out of this study. I
had this drive before, but I had this thing holding me back. And it's like the gates
were opened and I just said, "Fuck it," and ran. So I do end up butting up against
triggers and stuff like that occasionally. But it's because I'm doing way more.”
Improvement in self-awareness. All study participants (n=17) experienced an
improvement in self-awareness or understanding as reported in LTFU interviews. The following
quotes highlight some of the ways in which participants gained insight into themselves and the
processing of their trauma.
“I could see why I feel the way I do about a lot of things. I can now understand a
lot of things about myself.”
“I was slipping down a really bad hole just in life. So I feel like I've gotten my life
back that I lost. I had this life before I went to Afghanistan, I hadn't seen any part
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of that person in the mirror since. So to me it feels like I'm kind of getting back to
my old self slowly over time.”
“I have felt like I've come a long ways. I don't want to grow stagnant. I'd like to
keep going and grow more and evolve.”
“It probably is linked to these past events and now it's just a matter of focusing on
that and giving myself new meanings behind it.”
“I had a tragic childhood and this kind of woke me up to it. You can see yourself
like you can read a book and see everything that you stand for and kind of analyze
your own self, your own thought, your own reasoning.”
“It seemed before I was feeling as though I was like kind of self-conscious, or
maybe I wasn't deserving of it. And now it seems I'm more confident. I have less
to think about. I don't have regrets or anything like that, or I'm not thinking about
other stuff. I'm not feeling self-conscious about being flawed or anything like
that.”
Overall experience with the study. Nearly all participants (n=16) reported that the
MDMA played a major role in their treatment bringing about change and most (n=14) discussed
the importance of the therapists.
“It was really important to have a mother and father in the room with me. That
was one of the most powerful parts for me.”
“It’s not a clouded, druggy, trippy kind of thing. It’s a weird way of your mind
showing you your own memories. And then you can relive it; you can feel it, you
can see it, you can smell it. But yet, you’re safely away from it and you’re still
thinking from your adult mind, not from a child’s mind, not understanding what’s
going on. You can see it.”
“I think that the MDMA gave me the ability to feel as though I was capable and
safe of tackling the issues. Whereas before I feared those thoughts and I tried to
avoid them at all times, and avoid things that reminded me of those thoughts,
which is very typical of PTSD...I think it allowed me to feel safe in my space. Of
being able to fight it. I felt like I had the ability and tools, whereas before I was
unarmed, unarmored, and had no support. And this type of environment, with
ya'll, the catalyst drug, and everything else, it felt as though I had backup. Now it
was safe and I had my tools and weapons to be able to tackle the obstacles that I
never had before.”
“There are no words that are going to explain this, but I have never in my life
relaxed like I did during this. Like what you would feel in your mommy’s tummy,
back in the womb, very safe, very warm. And for me to get where I needed to be
within my own mind, I had to relax that way.”
45

“I wouldn't be doing any of this stuff that I'm doing if it weren't for you guys,
seriously. I owe you guys both my life.”
“It is the one thing that has helped me since 1995. The one thing that I’ve tried
and done that’s helped in any kind of way. None of the drugs they gave me,
psychology, seeing a psychiatrist, none of it’s the only thing I felt like I got
benefit from. Not because it feels good or some kind of high. It helps.”
“I feel like this study helped speed up the processing and understanding because it
could have been...It took me four years to just talk, to bring it up, and I just think
it would have been several more years of painful maybe terrible therapy that went
nowhere. I feel like this therapy really helped me get past the tears and get right to
the problem and several other problems I didn't know were related to the feeling.”
Subject Recommendations. The primary recommendation from study participants is to
have continued sessions. This has been suggested in a number of ways including having one
more session in the same sequence, continuing sessions four times per year, or continued nonmedication sessions with the therapists. The following quotes are examples of some
recommendations from participants after they had completed the study.
“I think like now would be good. A year or so, because I think that it gives
enough time to like, if you like do one two three, and then you did the other ones,
you have to live through a rollercoaster for like months and months and months, I
really thought I was getting more crazy as we did more, like I was really starting
to lose it again. Like I thought, I think it was all part of the process or something.
And then it all started to level out again once it was, you know what I mean? We
really shook stuff up.”
“Maybe, where there was, like, a one year after the very last session reference
point, where you have a chance to spend a year working with the process, and
then come back to it to see where you're at and, maybe, get some useful insight in
ways or areas that you could be more active in bringing about the change that
you're trying to see in your life.”
“It could be a sort of an as-needed thing where, maybe somebody didn't need to
have any additional MDMA because things were going so well for them. But,
maybe, somebody else, they come up to another wall in their life, where they're
just unable to get past whatever is in front of them, and the MDMA has helped
them get through these walls before. So having the option of being able to use that
as a medicine to get through the wall, and association with the therapy again.”
“That’s why I think one more session, I don’t want to go anymore than that, but
that would do as I call it put icing on the cake.”
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“I think like 6 months later, I would say around February, March that time period
I was really wishing to have those feelings again. If not to discover anything new,
but to give myself a break, because it was such a break from that mental anguish
all the time.”
“Because I was just thinking like a year from now would be a good time to try
and grow even further.”
“And I would think the first three and then a year to process that. Because I think
so much happens and then to do my quarterly for the rest of my life, well our
point's a year. But I think like even doing the three or six in a row and then let
process that per year and then maybe do that next year maybe do them quarterly
and then yearly early updates.”
“I think an additional session later on, maybe after there's been time to process
and think about things, think about how it's all affected, maybe as another push. I
don't know if that'd be a year, or two years.”
Summary
The main finding that emerged from this study is that mystical-type phenomena is not an
essential experience for lasting symptom improvement for PTSD, but rather that there is a
favorable benefit ratio for PTSD treatment with MDMA in a supportive environment, in
conjunction with psychotherapy. The qualitative data from LTFU interviews reveal that the study
provided beneficial change for all participants. Although the FDA approves treatment based
solely on safety and efficacy, qualitative accounts of the lasting benefit are vital in understanding
how to continue providing adequate support to patients, and set them up for long-term health.
Based on a Pearson correlation analysis, the current study found no correlation between
MEQ30 scores and improvement in CAPS scores from baseline to year-long follow up (r=0.036, p=0.890) or MEQ30 scores and long-term positive symptom improvement (Sx+(LT)) as
reported in LTFU interviews (r=0.171, p=0.512). Therefore, mystical experiences are not
correlated with the enduring symptom improvement participants in the Phase 2 trials described.
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CHAPTER V
Discussion
Major Findings Relative to the Literature Review
The results of the current study align with previous neurobiological research on
psychedelics (Carhart-Harris, et. al., 2014, Beck, 1994). MDMA does not induce mystical
experiences as profoundly as other psychedelics such as LSD, Psilocybin, Ayahuasca, or
Ketamine. While some research studies conclude that MDMA is an auspicious therapeutic agent,
it has mostly been used recreationally. This study aimed to provide evidence for the benefits of
MDMA without the influence of its recreational use impeding on its illegality. The current study
is significant because the use of MDMA-assisted psychotherapy, in a controlled setting that
provided a combination of psychological and pharmacological treatments, proved fruitful in
achieving the desired effects of MDMA-assisted Psychotherapy on Patients with Recurring
treatment resistant PTSD Symptoms. Findings from this study support that this treatment method
when used with chronic, treatment-resistant PTSD can be safely applied in supervised settings
with no drug-related serious adverse events occurring.
Efficacy failed to reach statistical significance (p = 0.171) as measured by the primary
outcome measure whereas self-assessment of the participants’ PTSD symptoms, as measured by
the LTFU self-reporting questionnaire, showed beneficial results for the participants in this
study.
Figure 3 demonstrates mean mystical experience scores from existing studies on other
psychedelics, including Ketamine, Ayahuasca, LSD, and Psilocybin. Compared to other
entactogens, MDMA appears to insight a smaller percentage of total possible mystical
experience score. This finding sheds light on why MDMA is useful for PTSD as compared to
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other psychedelic substances. The post-session mystical experience score (mean percentage) that
compared Ketamine (Dakwar, et al., 2014), Ayahuasca (Bouso, et al., 2016), LSD (Liechti, et al.,
2016), Psilocybin (Griffiths, 2008), and MDMA (current study) documented positive outcomes
(See Figure 3).
Figure 3: Post-session mystical experience score (mean percentage) comparing five researched
entactogens

It is well worth mentioning that no participants in this study reported any harm or decline
from their participation and all participants reported various degrees of benefit. Often these
benefits extended beyond decreased PTSD symptoms. Considering the degree of support,
monitoring and follow-up, these findings are not unusual; many forms of psychotherapy produce
benefits in terms of psychological growth and development that are not restricted to
improvements in a specific disorder or problem that was identified at the original target of
therapy. These findings, however, are of particular significance for the present study because
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they indicate a valuable feature of MDMA-assisted psychotherapy that extends beyond the core
issues. Some of the areas of benefit that were endorsed on the LTFU questionnaire, such as an
increased self-awareness, improved relationships, an enhanced spiritual life, and more
involvement in the community or world, represent effects that are not fully measured by the
PTSD symptom scales.
Findings from this study are consistent with Mithoefer, M.C., Wagner, M.T., Mithoefer,
A.T., Jerome, L., & Doblin, R. (2012) who found in their study that on average subjects
maintained statistically and clinically significant improvements in PTSD symptom relief and
reported no harm from participating in their study. The Mithoefer et al. study, like the present
study, showed that no participant developed a problem with any illicit substance after MDMAassisted psychotherapy, which supports the hypothesis that MDMA can be administered in a
regulated, clinical setting without creating a dependence or addiction.
The current study also supports findings from Maclean, Johnson, Leoutsakos, & Griffiths
(2012), which shows that the MEQ30 is a reliable and valid measure that correlates with other
mysticism scales, and that it is a useful tool in studying psychedelic experiences. Also the current
study’s findings are consistent with Thomas, Lucas, Capler, Tupper, & Martin (2013) study on
problematic substance use and stress that after four days of group counseling and two ayahuascaassisted therapy sessions, participants showed improvements on scales assessing hopefulness,
empowerment, mindfulness, and quality of life meaning and outlook. Feedback from the LTFU
interviews almost mirrored Thomas et al. (2013) findings.
The worthiness of the current study is validated by participant comments and feedback on
the LTFU interviews and questionnaire describing the positive MDMA treatment effects. Their
descriptive feedback provides an important context in which the outcome data is evaluated and
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understood. Their benefits endorsed and described extended beyond the realm of symptom
reduction. Specifically, the participants shared deeply meaningful therapeutic experiences and
ongoing improvements in their lives. The majority of participants in the current study endorsed
benefits such as, “increased self-awareness and understanding” and “enhanced well-being.”
These responses, similar to other researchers’ findings, point to a process of psychological and
spiritual exploration and growth that could logically be expected to facilitate trauma processing
and symptom reduction, and to promote healthy psychological development.
Weaknesses and Limitations
The primary limitation to this study was the lack of control group for the follow-up
interviews. It would be ethically problematic under the National Social Work Code of Ethics and
American law to conduct a placebo control group over such a long period of time. Other
limitations also reflect the preliminary nature of this study. Data were extrapolated from a larger
qualitative exploration that did not focus on MDMA-induced mystical experiences. Although the
basic dimensions of the MEQ30 were utilized, shortening the initial 100-item questionnaire
(SOCQ-100) may have also impacted our capacity to obtain more nuanced information about the
psychoactive effects, particularly when comparing the difference in dosage.
Another limitation of the current study was the varying lengths and nature of interviews.
Although most interviews covered similar topics, it is possible some participants experienced
certain phenomena, but did not express them. Data analyzed the number of times a participant
mentioned long-term, positive symptom change in their LTFU interview, however, this number
may not be directly related to the realistic improvement of their symptoms. Therapists from the
study gave the LTFU interviews; while this had some benefits for rapport and safety, it may have
altered responses.
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The sample was small (n=17) and homogenous, reflecting a largely Caucasian
demographic (n=15). Current research about these medications falls short regarding issues of
diversity. No study addresses race, socioeconomic status, gender, ability or other important
identities when assessing effectiveness of this treatment. While this study does not purport to
show definite differences in experiences of varying demographics, it may open doors to the kind
of future research that needs to be conducted. Information about other races or multiculturalism
is lacking.
Demographic information such as religious affiliation, spiritual beliefs, or attachment
history was also omitted from the data collection. This information might have provided more
insight about mystical experience scores and personal predispositions towards lower or higher
scores.
Implications for Social Work
It is possible that the changes observed by participants in this study were dependent on a
related experience of emotional safety and engagement in therapy, but these do not match the
criteria for mystical experiences on the MEQ30. The results support the goal of MDMA-assisted
therapy, which is not to have a mystical experience, but rather to confront and work through
trauma. The minimal mystical-type effects MDMA induces may relate to reasons why this
particular entactogen is so useful, specifically for PTSD. Instead of mystical experiences,
MDMA promotes a profound feeling of safety which allows people with PTSD to confront and
make meaning of their trauma without being physiologically activated. Some PTSD symptoms
are the very obstacles to treating it, such as avoidance, dissociation, or panic attacks. MDMA
may prevent these defenses from occurring, allowing patients to benefit from therapy in a way
their PTSD has prevented in the past.
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The implication of the current study for social work is, therefore, that MDMA-assisted
psychotherapy is not beneficial because of an inherent effect of the psychedelic on the brain, but
rather, that participants could access and benefit from talk-therapy.
Future questions. Future research can evaluate whether mystical-type effects influence
the therapeutic effects of MDMA in larger clinical samples and in other clinical frameworks. The
upcoming Phase 3 trials provide a great opportunity to continue learning about the participant
experience and external factors that contribute to persistence of benefit. Although mystical
experiences are not correlated with symptom improvement, the LTFU interviews revealed the
importance of feeling safe and calm when working through trauma. Future research should
investigate the influence of MDMA on the amygdala and other parts of the brain or use
qualitative measures to explore the implications of feeling safe during MDMA-assisted therapy.
Phase 3 trials also offer an important opportunity to explore how participant attachment styles,
religious or spiritual histories, or sociopolitical identities may relate to long-term treatment
outcomes.
Long-term follow-up studies allow researchers to investigate the lasting efficacy of
treatment and predict the need for maintenance treatment. A thorough long-term qualitative
investigation in Phase 3 and further exploration of Phase 2 would supplement the existing data
surrounding MDMA-assisted psychotherapy.
Conclusion
In the realm of psychedelic-assisted therapy, mystical experiences have been linked to
long-term positive treatment outcomes (Pahnke, 1963; Doblin, 1991). The current study presents
results from a correlation analysis of the Mystical Experience Questionnaire (MEQ30) with
PTSD treatment outcomes to determine if lasting symptom improvement is related to mystical
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experiences occasioned by MDMA-assisted therapy. Many people report mystical experiences
during their time under the influence of psychedelics; however, that experience with MDMA is
not correlated with lasting symptom change as reported by participants during LTFU interviews
and Clinician-Administered PTSD Scale (CAPS) score improvement.
PTSD has plagued people since the beginning of humanity and there are still not
sufficient treatment options for this complex mental disorder. MDMA-assisted psychotherapy
has emerged as a promising option to permanently reduce PTSD symptoms. MAPS Phase 2 trials
showed that MDMA-assisted psychotherapy is reliable, safe, effective, and offers enduring
benefit, without necessitating complete mystical experience.
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